BiotechTube
Home/Affimed/Dr. Andreas Rutten
DA

Dr. Andreas Rutten

Chief Development Officer

Affimed

Therapeutic Areas

OncologyHematological Malignancies

Affimed Pipeline

DrugIndicationPhase
AFM13Relapsed/Refractory Hodgkin LymphomaPhase 2
AFM24EGFR-positive Solid TumorsPhase 1/2a
AFM28Acute Myeloid LeukemiaPhase 1/2

Leadership Team at Affimed

DA
Dr. Andreas Harstrick
Chief Medical Officer (Acting CEO)
DW
Dr. Wolfgang Fischer
Chief Operating Officer
DT
Dr. Tilman Baumann
Chief Business Officer
DA
Dr. Adi Hoess
Former Chief Executive Officer
View full Affimed profile